Innovative Cardiovascular Solutions, a Kalamazoo, Mich.-based clinical stage company developing the Emblok™ Embolic Protection System, completed a Series C round of financing, raising a total of $8M.
The company intends to use the funds to conduct clinical trials in the U.S. and Europe as well as manufacturing and operational activities.
Led by R. Kevin Plemmons, co-founder and CEO, Innovative Cardiovascular Solutions provides the Emblok system, which is designed for use in Transcatheter Aortic Valve Replacement (TAVR) and other structural heart procedures where embolic protection is required.
The Emblok system is an embolic protection device designed to offer complete circumferential aortic collection while protecting the cerebral, abdominal and peripheral vasculature from liberated embolic debris. In addition, the system features an integrated 4 Fr radiopaque pigtail catheter which provides the physician constant visualization while eliminating the need for unnecessary dye injections to verify positioning. The entire system is 11 Fr and allows two devices – the embolic filter and pigtail catheter – to be deployed through a single femoral puncture site.
Emblok is available for investigational use only and is not approved for sale.